Minerva Neurosciences (NERV) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Minerva Neurosciences (NERV) Annonuces Significant Top-Line Data from MDD with MIN-202 Phase 1b
March 11, 2016 8:33 AM ESTMinerva Neurosciences, Inc. (NASDAQ: NERV) announced positive top line results from a Phase Ib clinical trial in major depressive disorder (MDD) with MIN-202 (JNJ-42847922), a selective orexin-2 receptor antagonist under joint development with Janssen Pharmaceutica NV.
Treatment with MIN-202 was observed to result in consistent improvements in the symptoms of depression in MDD patients in this trial, said Dr. Remy Luthringer, president and chief executive officer of Minerva. The results pave the way to initiate a Phase IIb trial in patients suffering from MDD. These improvements support the potential of MIN-202 to have a... More
